Evidence map›Paper›PMID 40208541›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2025

Histological and Histochemical Methods for the Evaluation of Tissue Engineered Skin Substitutes.

Fernando Campos, Víctor Carriel, Fabiola Bermejo-Casares, Jesús Chato-Astrain, Miguel Alaminos

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Fernando Campos *Tissue Engineering Group, Department of Histology, University of Granada, Granada, Spain.
Víctor Carriel *Tissue Engineering Group, Department of Histology, University of Granada, Granada, Spain.
Fabiola Bermejo-CasaresTissue Engineering Group, Department of Histology, University of Granada, Granada, Spain.
Jesús Chato-AstrainTissue Engineering Group, Department of Histology, University of Granada, Granada, Spain. jchato@ugr.es.
Miguel AlaminosTissue Engineering Group, Department of Histology, University of Granada, Granada, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A thorough evaluation and characterization of advanced therapy medicinal products (ATMPs), including tissue-engineered skin substitutes (TESS), is an essential requirement of the European and National Medicines Agencies. Although clear regulatory criteria have been established for different parameters such as stability, sterility or viability, the histological characterization of bioengineered tissues remains inadequately defined. Histological analyses are crucial for assessing both the in vitro features and in vivo behavior of TESS. This chapter describes the essential histological methods used for assessing TESS, including hematoxylin and eosin staining, and several methods focused on the analysis of specific components of the skin cells and extracellular matrix, such as Picrosirius Red for collagen fibers, Fontana Masson Picrosirius for melanin and collagen, Verhoeff for elastic fibers, Alcian Blue for proteoglycans, and Periodic acid-Schiff for glycoproteins. Relevant immunohistochemical methods for the identification of some specific markers are also included in this chapter. These methods provide a comprehensive practical approach to assessing both in vitro and in vivo histological features and evolution of TESS.

Indexed as

SkinSkin, ArtificialTissue EngineeringAnimalsCollagenExtracellular MatrixHumansImmunohistochemistryStaining and LabelingCollagenAdvanced therapy medicinal productsHistochemistryImmunohistochemistrySkin histological analysisSkin tissue engineering

Identifiers

PMID40208541

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.